Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference
Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025
Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology Congress 2025
pharmaceutical-investing Corvus Presents Updated Biomarker and Clinical Results from Lead Pipeline Programs
